X4 Pharmaceuticals Files 8-K on Security Holder Vote Matters
Ticker: XFOR · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1501697
| Field | Detail |
|---|---|
| Company | X4 Pharmaceuticals, Inc (XFOR) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, sec-filing
TL;DR
X4 Pharma is holding a shareholder vote on June 9th - expect news soon.
AI Summary
On June 11, 2025, X4 Pharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing date for the earliest event reported was June 9, 2025. The company, formerly known as Arsanis, Inc., is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This filing indicates that X4 Pharmaceuticals is seeking approval from its security holders on certain matters, which could impact corporate governance and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 001-38295 — SEC File Number (Identifies the company's filing history with the SEC.)
- 27-3181608 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- X4 Pharmaceuticals, Inc. (company) — Registrant
- Arsanis, Inc. (company) — Former company name
- June 11, 2025 (date) — Date of report
- June 9, 2025 (date) — Date of earliest event reported
- 61 North Beacon Street, 4th Floor Boston, Massachusetts 02134 (address) — Principal executive offices
- 27-3181608 (ein) — IRS Employer Identification No.
FAQ
What specific matters are being submitted for a vote by X4 Pharmaceuticals' security holders?
The filing states 'Submission of Matters to a Vote of Security Holders' but does not specify the exact matters in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 9, 2025.
What is the principal executive office address for X4 Pharmaceuticals, Inc.?
The principal executive offices are located at 61 North Beacon Street, 4th Floor, Boston, Massachusetts 02134.
What was X4 Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Arsanis, Inc.
What is the SEC file number for X4 Pharmaceuticals, Inc.?
The SEC file number is 001-38295.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding X4 Pharmaceuticals, Inc (XFOR).